Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating venetoclax + azacitidine with AZA + HAG in elderly or unfit newly diagnosed AML
ChiCTR2400094653Phase 2Recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Dec 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, azacitidine, homoharringtonine, cytarabine and filgrastim in acute myeloid leukemia (AML), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Composite complete remission rate after 4 cycles. Started Dec 2024; status: recruiting.
02
Drugs
venetoclaxazacitidinehomoharringtoninecytarabinefilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400094653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094653.